Loading
Biomed Valley Discoveries
Biomed Valley Discoveries is a Kansas City company owned through the Stowers Institute for Medical Research. Its main medicine, ulixertinib, blocks ERK, the last step of a growth signalling chain that is switched on in many cancers and in histiocytosis.
Also called: BioMed Valley Discoveries, Inc.Biomed Valley Discoveries Inc.BVD
Overview
Biomed Valley Discoveries, Inc. (BVD) describes itself as a clinical-stage biotechnology company based in Kansas City, Missouri, wholly owned by a supporting organisation of the non-profit Stowers Institute for Medical Research and funded through American Century Investments. Its lead programme is ulixertinib (BVD-523), which the company calls a highly selective ERK1/2 inhibitor, in phase 2 development; its website lists histiocytosis (NCT06411821), adult and paediatric low- and high-grade glioma (NCT05804227) and myelofibrosis with ruxolitinib (NCT06773195) as its priorities, and says a paediatric low-grade glioma trial is planned for 2026. It also lists TEM8/ANTXR1 antibodies for antibody-drug conjugates (preclinical) and a Clostridium novyi-NT bacterial programme whose phase 1 is complete. The FDA designated ulixertinib an orphan drug for BRAF-mutant melanoma in 2013, and on 27 August 2026 granted the company a designation for malignant glioma for a product it describes as a reversible ATP-competitive ERK1/2 inhibitor.
Headquarters
Kansas City, MO, US
Scorecard
All companies#465of 1706 companies, score 9
- phase 1/2 +1
- targets +4
- modalities +2
- 24-month regulatory events +2
0 approved, 0 in phase 3, 1 earlier, 2 targets, 0 registry studies. Formula on the scorecards page.
Type
Website
Products
1Phase 2Oral small-molecule kinase inhibitor
Ulixertinib is an experimental tablet from Biomed Valley Discoveries that blocks ERK, the last switch in a growth signalling chain that drives some cancers. It is being tested in histiocytosis and in gliomas.
Notes
- The 2026 FDA record does not name the product; ulixertinib is the only ERK1/2 inhibitor on the company's pipeline. The window-of-opportunity glioma trial NCT05804227 is sponsored by MD Anderson Cancer Center and the histiocytosis trial NCT06411821 by Memorial Sloan Kettering. Read on 4 November 2026.
Connected
7Similar pages
- CancerRosai-Dorfman-Destombes disease
Shares Erdheim-Chester disease, Small-molecule kinase inhibitors.
- CancerMultisystem Langerhans cell histiocytosis (with or without risk-organ involvement)
Shares Erdheim-Chester disease, Small-molecule kinase inhibitors.
- CancerBRAF V600-mutant melanoma
Shares Ulixertinib, Erdheim-Chester disease, Small-molecule kinase inhibitors.
cancers
fronts
technologies
targets
drugs
Phase 2Oral small-molecule kinase inhibitor
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
biomed-valley.com · 2
US Food and Drug Administration · 2
A source that has moved or gone is reported by the weekly link check. /audit/